With Roche Deal Signed, Tekmira Says It Has Funds to Last Until Mid-2011

Tekmira made the disclosure as part of its first-quarter earnings release, which showed a 425 percent rise in net loss as operations swelled after its merger with Protiva Biotherapeutics last year.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.